Racial and Ethnic Disparities in the Context of New and Emerging Treatments for Hemophilia

Statement of Need

New and emerging therapies for hemophilia are transforming clinical pathways in patient care. Such therapies include extended half-life products, non-factor/rebalancing therapies, and even gene therapies. But while this expanding armamentarium is a triumph in the evolution of hemophilia prophylaxis and treatment, patient access to such breakthroughs remains limited, especially in underserved populations.

In this 30-minute CME Outfitters Snack activity, two experts in hemophilia explore the reasons behind inequities in care. Indeed, non-White patients with hemophilia have the highest rates of mortality, chronic pain, impaired functional status, and hemophilia-related distress. Beyond illuminating the scope of the problem, the faculty provides several actionable strategies to help practicing clinicians ensure equitable care for all patients.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

Implement strategies to help achieve racial and ethnic equity in the care of patients with hemophilia

Financial Support

Supported by an educational grant from Novo Nordisk, Inc.

Target Audience

Hematologists, hematologist/oncologists, physician associates (PAs), nurse practitioners (NPs), and nurses

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.50 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists (ACPE) 0.5

This application-based activity is approved for 0.50 contact hours (0.05 CEUs) of continuing pharmacy credit (JA0007185-0000-24-045-H01-P).

Physician Assistants (AAPA): 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until 07/22/2025. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 0.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Interprofessional (IPCE) 0.5

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education Credit for learning and change.

Disclosure Declaration

Ms. Bloomberg reports the following financial relationships:

Advisory Board: Genentech, Inc.; Novo Nordisk; Pfizer Inc.; Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.

Speakers Bureau: Bayer Corporation; Genentech, Inc.; Novo Nordisk; and Sanofi

Dr. Chrisentery-Singleton reports the following financial relationships:

Advisory Board: Bayer Corporation; BioMarin; CSL Behring; Genentech, Inc.; HEMA Biologics; Kedrion; Novo Nordisk; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Research Support: BioMarin; Pfizer Inc.; and Spark Therapeutics, Inc.

Speakers Bureau: BioMarin; CSL Behring; Genentech, Inc.; Grifols; Novo Nordisk; Octapharma USA; Spark Therapeutics, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

The following individuals have no financial relationships to disclose:

Rebecca Vargas-Jackson, MD  (Peer Reviewer)
Shirley Michelle Franks, MSN, APRN, FNP-BC (Peer Reviewer)
Thomas Mitchell, MSW (Planning Committee)
Warren Beckman (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

SN-240-072424-68

Racial and Ethnic Disparities in the Context of New and Emerging Treatments for Hemophilia

Faculty

Statement of Need

Learning Objectives

Financial Support

Target Audience